Amgen Jun 7, 2022 Mirati Hoping to Set Apart Adagrasib in Competitive KRAS-Mutant NSCLC Market With CNS Activity Data Premium Jun 6, 2022 Vectibix Outperforms Avastin in First-Line RAS-Wildtype Left-Sided Colorectal Cancer Premium May 12, 2022 Bristol Myers Squibb Scoops Up Rights to BridgeBio's SHP2 Inhibitor May 6, 2022 Drugmakers Come Together Hoping to Formalize MRD as Surrogate Endpoint in AML Trials Apr 28, 2022 Amgen Q1 Revenues Increase 6 Percent With Strong Growth in Lumakras Sales Apr 15, 2022 Novartis Enters KRAS G12C Space With Positive Phase I/II Data in Lung, Colorectal Cancer Apr 11, 2022 One-Third of KRAS-Mutant NSCLC Patients in Amgen's Lumakras Trial Alive After Two Years Premium Feb 18, 2022 Amgen Expanding Enrollment in Lumakras Trial After Promising Data in KRAS-Mutant Pancreatic Cancer Premium Jan 21, 2022 In Brief This Week: AstraZeneca, Daiichi Sankyo, Orgenesis, Amgen Jan 13, 2022 BridgeBio, Amgen to Study SHP2 Inhibitor, Lumakras Combo in KRAS-Mutant Tumors Jan 12, 2022 JP Morgan Healthcare Conference Day 2: Ideaya, Amgen, Revolution Medicines, Monte Rosa, and More Jan 10, 2022 Amgen's Lumykras Garners European Commission Conditional Approval for KRAS-Mutated Lung Cancer Jan 4, 2022 MSK, Amgen Explore Lumakras Combination Regimens to Overcome KRAS Inhibitor Resistance Premium Dec 15, 2021 Amgen Turning to Combination Strategies After Limited Lumakras Efficacy in KRAS-Mutated Colon Cancer Nov 12, 2021 CHMP Recommends Amgen's Lumykras for KRAS G12C-Mutated NSCLC Sep 21, 2021 Verastem Oncology, Amgen Partner to Study RAF/MEK Inhibitor With Lumakras in NSCLC Sep 21, 2021 ESMO Studies Investigate KRAS-Mutated Cancers in Targeted Combination Rx, Chemo Trials Premium Sep 10, 2021 UK's MHRA Grants Early Access to Amgen's Lumakras for KRAS-Mutant Lung Cancer Jun 24, 2021 Researchers Make Progress in Characterizing Diverse Mechanisms of KRAS Inhibitor Resistance Premium Jun 5, 2021 ASCO Study Details Activity of Amgen's Lumakras, First Approved KRAS-Targeted Drug, in NSCLC Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week: Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
